MMI presents data for ruthenium chemotherapies

 

TIDMMMG 
 
 
Medical Marketing Int'l Group PLC 
20 April 2009 
 
? 
MMI presents data for ruthenium chemotherapies at leading US cancer conference 
 
 
 
 
Monday, 20 April 2009 - Medical Marketing International Group plc ("MMI" or the 
"Company") (AIM:MMG), the life sciences company focused on the development of 
drugs for cancer, announces that data relating to its ruthenium chemotherapies 
is being presented in a poster at the American Association of Cancer Research 
Annual Meeting on 18-22 April 2009 in Denver, Colorado. 
 
 
The poster is available under the News section of the Company's website, 
www.oncosense.com. 
 
 
On 4 March 2009, MMI announced the findings of pre-clinical studies of its 
ruthenium compound ONCO 4417 which demonstrated that ONCO 4417 induces DNA 
damage to levels comparable with that of cisplatin and suggest that the induced 
DNA damage may directly or indirectly result in apoptosis (programmed cell 
death). Furthermore, as ONCO 4417 does not appear to share cross-resistance 
mechanisms with cisplatin, it is likely that the damage may provide novel cancer 
targets for our ruthenium compounds. A summary of this work is included in the 
poster. 
 
 
MMI continues to focus on investigating the mechanisms responsible for repair of 
ruthenium chemotherapy induced damage. The findings will be used to target our 
ruthenium compounds to cancers where the drug will have most effect and to 
investigate the combination of ruthenium chemotherapy with other drug agents. 
 
 
 
Enquiries: 
 
 
+----------------------------------------------------+-----------+ 
| Medical Marketing International Group plc          | Tel: +44  | 
| Phil Cartmell, Non-executive Chairman              | (0) 1223  | 
| Mark Burton, Chief Technical Officer               | 477 677   | 
| Rob Sprawson, Chief Financial Officer              |           | 
+----------------------------------------------------+-----------+ 
|                                                    |           | 
+----------------------------------------------------+-----------+ 
| FinnCap                                            | Tel: +44  | 
| Sam Smith/Charlie Cunningham                       | (0)20     | 
|                                                    | 7600 1658 | 
+----------------------------------------------------+-----------+ 
|                                                    |           | 
+----------------------------------------------------+-----------+ 
| Financial Dynamics                                 | Tel: +44  | 
| Emma Thompson                                      | (0)20     | 
|                                                    | 7831 3113 | 
+----------------------------------------------------+-----------+ 
 
 
 
 
About MMI 
Medical Marketing International Group plc ("MMI") is a life sciences company 
that identifies, acquires and develops world-class compounds and technologies 
for the treatment of cancer. The Company manages the preclinical and early 
clinical development of drug candidates before pursuing licensing partners to 
manage late-stage development. Please visit www.mmigroup.co.uk for further 
information. 
 
 
Notwithstanding the inclusion on this release by MMI of a website address and/or 
another electronic address, MMI does not accept any notices or any other 
documents or communication via its website or other electronic address. All such 
notices, documents or communication shall be in hard copy format only. 
Accordingly the provisions of section 333 Companies Act 2006 allowing persons to 
communicate with MMI electronically shall not apply to MMI. 
 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NRADBGDSLBBGGCC